MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents
Méthodes de traitement de la maladie d'alzheimerInfo
- Publication number
- MA45149A MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
- Authority
- MA
- Morocco
- Prior art keywords
- alzheimer
- disease
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346818P | 2016-06-07 | 2016-06-07 | |
| US201662435531P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45149A true MA45149A (fr) | 2019-04-10 |
Family
ID=59067640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045149A MA45149A (fr) | 2016-06-07 | 2017-06-06 | Méthodes de traitement de la maladie d'alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200308259A1 (fr) |
| EP (1) | EP3464350A1 (fr) |
| JP (3) | JP2019517540A (fr) |
| KR (2) | KR20230165883A (fr) |
| CN (3) | CN114796481A (fr) |
| AU (2) | AU2017276656A1 (fr) |
| BR (1) | BR112018075300A2 (fr) |
| CA (1) | CA3026598A1 (fr) |
| IL (1) | IL263433B2 (fr) |
| MA (1) | MA45149A (fr) |
| MX (1) | MX2018015022A (fr) |
| WO (1) | WO2017211827A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| EP3696192A1 (fr) | 2019-02-15 | 2020-08-19 | Consejo Superior De Investigaciones Científicas | Cible thérapeutique et anticorps monoclonaux contre elle pour le diagnostic et le traitement de la maladie d'alzheimer |
| AU2020245031A1 (en) | 2019-03-26 | 2021-10-21 | Janssen Pharmaceutica Nv | Antibodies to pyroglutamate amyloid-β and uses thereof |
| CN110511276A (zh) * | 2019-08-13 | 2019-11-29 | 王跃驹 | 植物作为宿主在表达Aducanumab抗体中的应用 |
| US20220372123A1 (en) * | 2019-10-22 | 2022-11-24 | Biogen Ma Inc. | Anti-beta-amyloid antibody for treating alzheimer's disease |
| EP4185612A4 (fr) | 2020-07-23 | 2024-12-25 | Othair Prothena Limited | Anticorps anti-abêta |
| KR102321601B1 (ko) * | 2020-11-19 | 2021-11-05 | 주식회사 휴런 | 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법 |
| EP4351643A4 (fr) * | 2021-06-07 | 2025-08-06 | Biogen Ma Inc | Méthodes de traitement de la maladie d'alzheimer |
| US20250122146A1 (en) * | 2021-09-30 | 2025-04-17 | The Scripps Research Institute | Compounds for reducing neuroinflammation |
| EP4433511A1 (fr) * | 2021-11-19 | 2024-09-25 | AP Biosciences, Inc. | Anticorps bispécifiques ciblant cd137 et leurs utilisations dans l'immunothérapie anticancéreuse |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150087435A (ko) * | 2006-07-14 | 2015-07-29 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
| ES2439490T3 (es) | 2007-01-05 | 2014-01-23 | University Of Zurich | Anticuerpo anti-beta amiloide y usos del mismo |
| TR201812636T4 (tr) | 2010-10-11 | 2018-09-21 | Biogen Int Neuroscience Gmbh | İnsan anti-tau antikorları. |
| WO2014060444A1 (fr) * | 2012-10-15 | 2014-04-24 | Medimmune Limited | Anticorps anti-bêta-amyloïde |
| WO2014089500A1 (fr) * | 2012-12-07 | 2014-06-12 | Biogen Idec International Neuroscience Gmbh | Procédé de réduction des plaques amyloïdes cérébrales au moyen d'anticorps anti-ass |
| CA2896066C (fr) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Anticorps anti-tau humains |
| KR20240094017A (ko) * | 2014-02-08 | 2024-06-24 | 제넨테크, 인크. | 알츠하이머 질환을 치료하는 방법 |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
-
2017
- 2017-06-06 MA MA045149A patent/MA45149A/fr unknown
- 2017-06-06 MX MX2018015022A patent/MX2018015022A/es unknown
- 2017-06-06 EP EP17730427.6A patent/EP3464350A1/fr active Pending
- 2017-06-06 KR KR1020237040938A patent/KR20230165883A/ko active Pending
- 2017-06-06 KR KR1020197000443A patent/KR20190021311A/ko not_active Ceased
- 2017-06-06 IL IL263433A patent/IL263433B2/en unknown
- 2017-06-06 CN CN202210397569.0A patent/CN114796481A/zh active Pending
- 2017-06-06 AU AU2017276656A patent/AU2017276656A1/en not_active Abandoned
- 2017-06-06 JP JP2018563815A patent/JP2019517540A/ja not_active Withdrawn
- 2017-06-06 CA CA3026598A patent/CA3026598A1/fr active Pending
- 2017-06-06 CN CN201780044190.9A patent/CN109476730A/zh active Pending
- 2017-06-06 US US16/307,364 patent/US20200308259A1/en not_active Abandoned
- 2017-06-06 BR BR112018075300-9A patent/BR112018075300A2/pt unknown
- 2017-06-06 CN CN202210397435.9A patent/CN114931635A/zh active Pending
- 2017-06-06 WO PCT/EP2017/063711 patent/WO2017211827A1/fr not_active Ceased
-
2022
- 2022-02-25 US US17/681,011 patent/US20220281963A1/en not_active Abandoned
- 2022-08-15 JP JP2022129326A patent/JP2022145965A/ja not_active Withdrawn
-
2024
- 2024-08-29 AU AU2024216442A patent/AU2024216442A1/en active Pending
-
2025
- 2025-07-25 JP JP2025124966A patent/JP2025160337A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109476730A (zh) | 2019-03-15 |
| US20220281963A1 (en) | 2022-09-08 |
| CA3026598A1 (fr) | 2017-12-14 |
| JP2025160337A (ja) | 2025-10-22 |
| WO2017211827A1 (fr) | 2017-12-14 |
| IL263433B1 (en) | 2023-11-01 |
| JP2022145965A (ja) | 2022-10-04 |
| CN114796481A (zh) | 2022-07-29 |
| IL263433A (en) | 2019-01-31 |
| KR20230165883A (ko) | 2023-12-05 |
| CN114931635A (zh) | 2022-08-23 |
| JP2019517540A (ja) | 2019-06-24 |
| AU2024216442A1 (en) | 2024-10-17 |
| US20200308259A1 (en) | 2020-10-01 |
| IL263433B2 (en) | 2024-03-01 |
| MX2018015022A (es) | 2019-08-14 |
| EP3464350A1 (fr) | 2019-04-10 |
| BR112018075300A2 (pt) | 2019-04-30 |
| AU2017276656A1 (en) | 2018-12-13 |
| KR20190021311A (ko) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3645121A4 (fr) | Méthodes de traitement de la maladie de huntington | |
| MA45149A (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| EP3515505A4 (fr) | Traitement vaa de la maladie de huntington | |
| MA41115A (fr) | Procédé de traitement de la maladie d'alzheimer | |
| EP3458589A4 (fr) | Compositions et méthodes de traitement de la maladie de huntington | |
| EP3291815A4 (fr) | Méthodes de traitement d'une maladie neurodégénérative | |
| EP3490582A4 (fr) | Méthodes et compositions de traitement de maladie. | |
| EP3813808A4 (fr) | Méthodes de traitement de la toxicomanie | |
| EP3644996A4 (fr) | Procédés de traitement de la maladie de huntington | |
| EP3528852A4 (fr) | Méthodes et compositions pour le traitement de la maladie de fabry | |
| EP3294345A4 (fr) | Formulations de tpp1 et méthodes de traitement de la maladie cln2 | |
| EP3019523A4 (fr) | Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington | |
| EP3452166A4 (fr) | Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite | |
| EP3377118A4 (fr) | Méthodes pour traiter la maladie d'alzheimer et des troubles associés | |
| EP3402533A4 (fr) | Méthodes et compositions pour le traitement d'une maladie neurologique | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| EP2978446A4 (fr) | Procédés et agents pour le traitement de la maladie d'alzheimer | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| PL3347002T3 (pl) | Leczenie choroby alzheimera w konkretnej populacji pacjentów | |
| EP3386520A4 (fr) | Méthodes de traitement d'une maladie ou d'un trouble oculaire | |
| EP3393468A4 (fr) | Méthodes pour le traitement d'une maladie immunodéficiente | |
| EP3454793A4 (fr) | Bobines de traitement d'anévrisme | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| EP3634422A4 (fr) | Méthodes de traitement de la leucodystrophie | |
| MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique |